Drug treatments for covid-19: living systematic review and network meta-analysis

RAC Siemieniuk, JJ Bartoszko, D Zeraatkar, E Kum… - bmj, 2020 - bmj.com
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

S Juul, EE Nielsen, J Feinberg, F Siddiqui… - PLoS …, 2020 - journals.plos.org
Background Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has
caused extensive burden to individuals, families, countries, and the world. Effective …

The role of type I interferon in the treatment of COVID‐19

F Sodeifian, M Nikfarjam, N Kian… - Journal of medical …, 2022 - Wiley Online Library
Although significant research has been done to find effective drugs against coronavirus
disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 …

Systemic microvascular endothelial dysfunction and disease severity in COVID-19 patients: Evaluation by laser Doppler perfusion monitoring and cytokine/chemokine …

L Sabioni, A De Lorenzo, C Lamas, F Muccillo… - Microvascular …, 2021 - Elsevier
Background Microvascular dysfunction, serum cytokines and chemokines may play
important roles in pathophysiology of coronavirus disease 2019 (COVID-19), especially in …

Interventions for treatment of COVID-19: of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

S Juul, EE Nielsen, J Feinberg, F Siddiqui… - PLoS …, 2021 - journals.plos.org
Background COVID-19 is a rapidly spreading disease that has caused extensive burden to
individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently …

Synergistic interferon-alpha-based combinations for treatment of SARS-CoV-2 and other viral infections

A Ianevski, R Yao, E Zusinaite, LS Lello, S Wang, E Jo… - Viruses, 2021 - mdpi.com
Background: There is an urgent need for new antivirals with powerful therapeutic potential
and tolerable side effects. Methods: Here, we tested the antiviral properties of interferons …

Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease

N Todorović-Raković, JR Whitfield - Cytokine, 2021 - Elsevier
Interferons have prominent roles in various pathophysiological conditions, mostly related to
inflammation. Interferon-gamma (IFNγ) was, initially discovered as a potent antiviral agent …

The time to offer treatments for COVID-19

BT Ngo, P Marik, P Kory, L Shapiro… - Expert opinion on …, 2021 - Taylor & Francis
Background: COVID-19 has several overlapping phases. Treatments to date have focused
on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral …

Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality

K Honarmand, J Penn, A Agarwal, R Siemieniuk… - Journal of Clinical …, 2021 - Elsevier
Objective To describe the characteristics of Covid-19 randomized clinical trials (RCTs) and
examine the association between trial characteristics and the likelihood of finding a …

Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG

D Vázquez-Blomquist, A Hardy-Sosa, SC Baez… - Cells, 2022 - mdpi.com
HeberFERON, a co-formulation of Interferon (IFN)-α2b and IFN-γ, has effects on skin cancer
and other solid tumors. It has antiproliferative effects over glioblastoma multiform (GBM) …